中国经济网北京12月11日讯翱捷科技(688220.SH)今日股价下跌，截至收盘报86.71元，跌幅4.79%。该股 目前处于破发状态。 翱捷科技首次公开发行股票募集资金总额为68.83亿元，扣除发行费用后募集资金净额为65.46亿元。翱 捷科技最终募集资金净额比原计划多41.66亿元。该公司于2022年1月10日披露的招股说明书显示，其拟 募集资金23.80亿元，拟分别用于新型通信芯片设计，智能IPC芯片设计项目，多种无线协议融合、多场 域下高精度导航定位整体解决方案及平台项目，研发中心建设项目，补充流动资金项目。 翱捷科技首次公开发行股票的发行费用总额为3.37亿元，其中，保荐及承销费用3.10亿元。 翱捷科技于2022年1月14日在上交所科创板上市，发行的股票数量为4183.0089万股，发行价格为164.54 元/股，保荐人(主承销商)为海通证券股份有限公司(现更名为国泰海通证券股份有限公司)，保荐代表人 为王鹏程、龚思琪。 上市首日，翱捷科技开盘即破发，盘中最高价报130.11元，为该股上市以来最高价。 ...

经济观察网证监会网站显示，安徽金晟达生物电子科技股份有限公司2025年12月11日向安徽证监局办理 辅导备案登记，辅导机构为国泰海通证券股份有限公司。 ...

经济观察网证监会网站显示，全芯智造技术股份有限公司2025年12月11日向安徽证监局办理辅导备案登 记，辅导机构为国泰海通证券股份有限公司。 ...

Company Overview - Aopu Mai Biotechnology Co., Ltd. plans to acquire 100% equity of Plenitude Biopharmaceutical Technology (Shanghai) Co., Ltd. for a total transaction price of 1.451 billion yuan [1] - Aopu Mai specializes in cell culture products and clinical new drug process development and production services (CDMO), with its main revenue sources being cell culture products and CDMO services [1] - In the first three quarters of 2025, Aopu Mai's cell culture product business generated revenue of 239 million yuan, a year-on-year increase of 32.56%, making it the company's "core pillar" [1] Industry Context - The biopharmaceutical CDMO industry is highly competitive, with significant market segmentation between comprehensive CDMO leaders and specialized institutions [1] - The number of companies in the industry is large, with leading enterprises having a much higher global revenue share compared to second-tier companies [2] - Mergers and acquisitions among mid-tier companies can help expand business capabilities and improve industry efficiency [2] Acquisition Details - Aopu Mai's acquisition of Plenitude Biopharmaceutical aims to enhance its CDMO service capabilities and expand its customer base by integrating Plenitude's resources [2] - Plenitude Biopharmaceutical reported revenue of 187 million yuan and a net profit of 23.86 million yuan in the first half of 2025 [2] - The acquisition involves 31 parties and will utilize a differentiated pricing model, including stock and cash payments, to facilitate the transaction [3] Strategic Importance - The acquisition is seen as a key decision for Aopu Mai to achieve its strategic goals and further integrate its business operations [4] - Analysts suggest that the synergy post-acquisition will primarily manifest in customer flow between early-stage and later-stage business units, potentially enhancing profitability and increasing the share of overseas business [5]

证券日报网讯 12月10日晚间，天永智能发布公告称，公司近日收到国泰海通证券股份有限公司（简 称"国泰海通"）《关于更换上海天永智能装备股份有限公司持续督导保荐代表人的函》，国泰海通原指 定曾军、陈腾飞担任公司首次公开发行股票并上市项目保荐代表人，负责持续督导工作，持续督导期至 2020年12月31日。截至持续督导期届满，公司尚有部分募集资金未使用完毕，保荐机构将就其募集资金 使用情况继续履行持续督导的责任。近日，因陈腾飞工作安排变动，无法继续从事对公司的持续督导工 作，为保证持续督导工作的有序进行，国泰海通现委派保荐代表人沙成磊接替陈腾飞继续履行持续督导 工作。 （文章来源：证券日报） ...

上交所公开信息显示，当日该股因日换手率达32.27%上榜，营业部席位合计净卖出4215.46万元。 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交2.04亿元，其中，买入成交额为8071.51 万元，卖出成交额为1.23亿元，合计净卖出4215.46万元。 具体来看，今日上榜营业部中，第一大买入营业部为国泰海通证券股份有限公司总部，买入金额为 2284.96万元，第一大卖出营业部为华鑫证券有限责任公司上海茅台路证券营业部，卖出金额为3107.12 万元。 （原标题：华脉科技换手率32.27%，上榜营业部合计净卖出4215.46万元） 华脉科技(603042)今日上涨0.45%，全天换手率32.27%，成交额9.41亿元，振幅6.95%。龙虎榜数据显 示，营业部席位合计净卖出4215.46万元。 近半年该股累计上榜龙虎榜10次，上榜次日股价平均跌0.66%，上榜后5日平均涨0.13%。 资金流向方面，今日该股主力资金净流出7191.41万元，其中，特大单净流出3890.47万元，大单资金净 流出3300.94万元。近5日主力资金净流入2403.20万元。 10月25日公司发布的三季报数据显示，前三季度 ...

中国经济网北京12月9日讯奥浦迈(688293.SH)昨日晚间披露公告，上海证券交易所并购重组审核委员会2025年第20次审议会议 于12月8日召开，审议结果显示，公司发行股份购买资产符合重组条件和信息披露要求。本次交易尚需经中国证券监督管理委 员会同意注册后方可实施。本次交易能否完成注册以及最终取得完成注册的时间均存在不确定性。 重组委会议现场问询的主要问题： 1.请上市公司代表结合上市公司和标的公司业务布局、目前主要收入覆盖疾病领域、境内外收入结构差异等，说明协同效应的 实现方式以及风险揭示的充分性。请独立财务顾问代表发表明确意见。 2.请上市公司代表结合境外市场药物临床前CRO业务的市场竞争格局、标的公司的竞争优劣势、境外销售资源投入、客户结构 等情况，说明标的公司境外销售收入确认的合规性以及预测期境外业务增长的可持续性。请独立财务顾问代表、会计师代表和 评估师代表发表明确意见。 需进一步落实事项： 截至2025年6月30日，上市公司总股本为113,548,754股。上市公司控股股东为肖志华，实际控制人为肖志华、HEYUNFEN(贺 芸芬)夫妇。肖志华直接持有上市公司24.92%股份，肖志华、HEYUN ...

Core Viewpoint - The company, Jinqiao Information, has received approval from the Shanghai Stock Exchange for its application to issue A-shares to specific investors, pending final approval from the China Securities Regulatory Commission (CSRC) [1] Group 1: Issuance Details - The total amount to be raised from the issuance is not to exceed 615.38 million yuan, which will be allocated to projects including the upgrade of smart space solutions, AI research and development for industry applications, and replenishing working capital [1][2] - The issuance will involve no more than 35 specific investors, including qualified institutional investors such as securities investment fund management companies, securities companies, trust companies, financial companies, insurance companies, and qualified foreign institutional investors [2] - The pricing benchmark for the issuance will be set at 80% of the average trading price of the company's shares over the 20 trading days prior to the issuance date [2] Group 2: Shareholder Impact - The number of shares to be issued will not exceed 20% of the company's total share capital prior to the issuance, amounting to a maximum of 73,021,505 shares [3] - The controlling shareholder, Jin Guopei, currently holds 18.25% of the shares, and after the issuance, this percentage is expected to decrease to a minimum of 15.21% [3] - Measures will be taken to ensure the stability of the company's control, including limiting the number of shares that a single investor can subscribe to and requiring commitments from investors not to seek control of the company [4][5]

Group 1 - The company has successfully completed its initial public offering (IPO) of 40,001,000 shares at a price of 12.55 RMB per share, raising a total of 502,012,550 RMB, with a net amount of 423,821,978.59 RMB after deducting issuance costs [2][3] - The company has established a special account for the raised funds and signed a four-party supervision agreement involving the company, its wholly-owned subsidiary, the sponsor, and the bank [3][4] - The board of directors has authorized the management to handle the specific matters related to the capital increase and loan to the subsidiary, including signing relevant agreements [3][4] Group 2 - The special account for the raised funds has been opened at China Merchants Bank, with a balance of 0 RMB as of December 2, 2025, and is designated solely for specific investment projects [6][7] - The four-party supervision agreement outlines the responsibilities of each party in managing and supervising the use of the raised funds, ensuring compliance with relevant laws and regulations [6][7][8] - The agreement stipulates that any withdrawals exceeding 50 million RMB or 20% of the net raised funds must be reported to the sponsor, ensuring transparency and accountability [8] Group 3 - The company has approved the use of temporarily idle over-raised funds, up to 23.5 million RMB, for cash management purposes, including purchasing safe and liquid financial products [11][12] - A dedicated settlement account for cash management has been established under the original raised funds account, specifically for managing over-raised funds [12] - The company emphasizes that this cash management will not affect the ongoing investment projects or the normal operations of the business, aiming to enhance the efficiency of fund utilization and increase investment returns [15][16]

证券日报网讯 12月8日晚间，汉宇集团发布公告称，控股股东石华山先生本次解除质押股份11，950， 000股，占其所持股份比例5.83%，占公司总股本比例1.98%，解除日期为2025年12月5日，质权人为国 泰海通证券股份有限公司。 （文章来源：证券日报） ...